Phase II Adjuvant Cancer-specific Vaccine Therapy for Esophageal Cancer Patients Curatively Resected After Preoperative Therapy With Pathologically Positive Nodes; Possible Significance of Tumor Immune Microenvironment in its Clinical Effects.

Phase II Adjuvant Cancer-specific Vaccine Therapy for Esophageal Cancer Patients Curatively Resected After Preoperative Therapy With Pathologically Positive Nodes; Possible Significance of Tumor Immune Microenvironment in its Clinical Effects. Ann Surg. 2022 01 01; 275(1):e155-e162.

View in: PubMed

subject areas

Adult
Aged
Antigens, Neoplasm
Cancer Vaccines
Disease-Free Survival
Esophageal Neoplasms
Esophagectomy
Female
Follow-Up Studies
Humans
Immunotherapy, Active
Lymph Nodes
Lymphatic Metastasis
Male
Middle Aged
Neoadjuvant Therapy
Neoplasm Staging
Preoperative Care
Prospective Studies
Tumor Microenvironment

authors with profiles

Yusuke Nakamura